Current experiences with teclistamab in patients with multiple myeloma and renal impairment
Current guidelines, available data, and our clinical experience broadly support the feasibility and potential benefit of teclistamab for patients with MM and RI, including those on dialysis, providing appropriate precautions are taken. This expert opinion offers recommendations for optimizing the management of patients with MM and RI treated with teclistamab. Additional RW data will further inform the safety and efficacy profile of teclistamab in this patient population.
Authors
- Matthew J. Pianko (ORCID: https://orcid.org/0000-0001-9295-9750)
- Nelson Leung (ORCID: https://orcid.org/0000-0002-5651-1411)
- Ajay K. Nooka (ORCID: https://orcid.org/0000-0003-4165-6869)
- María‐Victoria Mateos (ORCID: https://orcid.org/0000-0003-2390-1218)
- Yael Chava Cohen (ORCID: https://orcid.org/0000-0002-9061-7287)
- Aurore Perrot (ORCID: https://orcid.org/0000-0003-0131-8689)
- Edward A. Faber
- Meletios A. Dimopoulos
Institutions
- Emory University (US)
- Tel Aviv University (IL)
- National and Kapodistrian University of Athens (GR)
- University of Michigan (US)
- WinnMed (US)
- Instituto de Investigación Biomédica de Salamanca (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- University of Cincinnati (US)
Publication Details
- Journal
- Expert Review of Hematology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1080/17474086.2025.2567296
- Citations
- 2
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.54